Latest Conference Articles

The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.

Immune Cell–Related Parameters May Serve as Biomarkers for Response to Nivolumab/Ipilimumab in Clear Cell RCC

February 19th 2022, 8:18pm

Genitourinary Cancers Symposium (ASCO GU)

Efficacy rates generated by the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) vary based on certain immune-cell related parameters in patients with advanced or metastatic clear cell renal cell carcinoma.

Frontline Nivolumab/Cabozantinib Combo Maintains Long-Term OS Benefit in RCC

February 19th 2022, 8:10pm

Genitourinary Cancers Symposium (ASCO GU)

The combination of nivolumab plus cabozantinib elicited a continued survival benefit compared with sunitinib in patients with untreated clear cell metastatic or advanced renal cell carcinoma.

Cabozantinib Dose Reduction Improves Survival in Patients With mRCC

February 19th 2022, 7:24pm

Genitourinary Cancers Symposium (ASCO GU)

A reduction in cabozantinib dosage because of toxicity demonstrated improved time to treatment failure and overall survival in patients with metastatic renal cell carcinoma.

Long-Term Data Show That Tivozanib Continues to Be Superior Vs Sorafenib in mRCC

February 19th 2022, 6:47pm

Genitourinary Cancers Symposium (ASCO GU)

Follow-up from the TIVO-3 trial showed that patients with pretreated relapsed/refractory renal cell carcinoma who received tivozanib were 5 times more likely to experience long-term progression-free survival compared with sorafenib.

Frontline Tivozanib Is Effective, Safe in Real-World Treatment of mRCC

February 19th 2022, 6:30pm

Genitourinary Cancers Symposium (ASCO GU)

Frontline tivozanib was noninferior to other tyrosine kinase inhibitors for the treatment of patients with metastatic renal cell carcinoma in a real-world setting.

Lenvatinib/Pembrolizumab Combo Effective in Advanced RCC, Regardless of Biomarker Status

February 19th 2022, 5:11pm

Genitourinary Cancers Symposium (ASCO GU)

Treatment with lenvatinib plus pembrolizumab was associated with a clinical benefit in advanced renal cell carcinoma, regardless of a patient’s biomarker status.

Second-Line Cabozantinib Produces Similar Outcomes in RCC, Regardless of Frontline Immunotherapy Choice

February 19th 2022, 5:00pm

Genitourinary Cancers Symposium (ASCO GU)

Treatment with cabozantinib (Cabometyx, Cometriq) in the second-line setting generated similar time-to-event end points and response rates in patients with advanced renal cell carcinoma, regardless of frontline immune-oncology combinations.

Neoadjuvant Enfortumab Vedotin Demonstrates Encouraging Activity in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer

February 19th 2022, 4:50pm

Genitourinary Cancers Symposium (ASCO GU)

Enfortumab vedotin produced promising antitumor activity when used as neoadjuvant treatment in patients with muscle invasive bladder cancer who were not eligible for cisplatin.

Frontline Olaparib/Durvalumab Misses PFS End Point in Platinum-Ineligible Metastatic Urothelial Carcinoma

February 19th 2022, 4:03pm

Genitourinary Cancers Symposium (ASCO GU)

The addition of olaparib to durvalumab did not result in a significant prolongation in progression-free survival compared with durvalumab alone in patients with previously untreated, platinum-ineligible metastatic urothelial carcinoma.

Addition of Sacituzumab Govitecan to Pembrolizumab Produces Promising Antitumor Activity in Metastatic Urothelial Cancer

February 19th 2022, 4:01pm

Genitourinary Cancers Symposium (ASCO GU)

Second-line sacituzumab govitecan plus pembrolizumab generated promising antitumor activity in patients with checkpoint inhibitor–naïve metastatic urothelial cancer.

Cabozantinib After Immunotherapy Failure Reassured as Safe, Feasible for mRCC

February 19th 2022, 3:51pm

Genitourinary Cancers Symposium (ASCO GU)

Updated data support the common use of cabozantinib in this setting without new safety signals in patients with metastatic renal cell carcinoma.

FDG and NaF PET/CT Imaging Prognostic for OS in Metastatic GU Cancers Treated With Cabozantinib/Nivolumab Combos

February 18th 2022, 11:15pm

Genitourinary Cancers Symposium (ASCO GU)

Fluorodeoxyglucose PET/CT and sodium fluoride PET/CT baseline functional imaging parameters and percent change in lesion number observed on follow-up imaging was linked with overall survival and found to be prognostic in patients with metastatic genitourinary cancers.

Dr. Iacovelli on Efficacy Findings From the ARIES Trial in Urothelial Cancer

February 18th 2022, 10:34pm

Genitourinary Cancers Symposium (ASCO GU)

Roberto Iacovelli, MD, PhD, discusses efficacy findings from the phase 2 ARIES trial in urothelial cancer.

Frontline Avelumab Misses 1-Year OS Mark, But Shows Notable Activity in Cisplatin-Ineligible, PD-L1+ Advanced Urothelial Cancer

February 18th 2022, 10:29pm

Genitourinary Cancers Symposium (ASCO GU)

Avelumab failed to demonstrate an improvement in overall survival at 1 year as frontline treatment in patients with cisplatin-ineligible, PD-L1–positive advanced urothelial cancer, though it did elicit a notable objective response rate.

Frontline Maintenance Avelumab Shows Consistent OS Benefit in Advanced Urothelial Cancer

February 18th 2022, 10:13pm

Genitourinary Cancers Symposium (ASCO GU)

The frontline maintenance combination of avelumab plus best supportive care continued to show an improvement in overall survival compared with BSC alone in patients with metastatic urothelial cancer who receive first-line chemotherapy.

Addition of Lenvatinib to Pembrolizumab Fails to Improve Survival in Advanced Urothelial Carcinoma

February 18th 2022, 9:10pm

Genitourinary Cancers Symposium (ASCO GU)

The combination of lenvatinib and pembrolizumab elicited comparable antitumor activity compared with placebo plus pembrolizumab as frontline therapy in patients with advanced urothelial carcinoma who were ineligible for platinum-based chemotherapy, according to data from LEAP-011.

Darolutamide Demonstrates Strong Safety Profile in mCRPC after Long-Term Analyses

February 18th 2022, 7:29pm

Genitourinary Cancers Symposium (ASCO GU)

Darolutamide produced a well-tolerated safety profile in patients with metastatic castration-resistant prostate cancer, according to pooled data from long-term analyses of 3 trials.

18F-rhPSMA-7.3 Imaging Favorable Detection Rates in Men with Recurrent Prostate Cancer

February 18th 2022, 4:36pm

Genitourinary Cancers Symposium (ASCO GU)

The utilization of 18F-rhPSMA-7.3 imaging displayed a clinically meaningful correct detection rate.

Darolutamide Maintains Efficacy in Patients with Comorbidities, Concomitant Medications in Nonmetastatic CRPC

February 18th 2022, 2:10pm

Genitourinary Cancers Symposium (ASCO GU)

The androgen receptor inhibitor darolutamide demonstrated continued efficacy and safety in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who have comorbidities or concomitant medications

Continuous Enzalutamide After Progression Improves PFS in Patients with mCRPC

February 18th 2022, 1:04am

Genitourinary Cancers Symposium (ASCO GU)

Continuous enzalutamide plus docetaxel and prednisone elicited progression-free survival improvement vs placebo with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer who had previously progressed on enzalutamide alone